Dodge & Cox’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$772M Sell
20,352,460
-44,650
-0.2% -$2.06M 0.41% 72
2026
Q2
$978M Buy
20,397,110
+1,063,360
+6% +$45.7M 0.51% 65
2026
Q1
$711M Buy
+19,333,750
New +$916M 0.39% 75

Other funds holding NVO

Dodge & Cox's NVO Position: Q3 2026 in Review

Dodge & Cox reduced its Novo Nordisk (NVO) stake by 0.22% in Q3 2026, selling an estimated $2.06M and leaving 20,352,460 shares worth $772M. The position accounts for 0.41% of the portfolio, ranked #72.

Dodge & Cox first reported a position in NVO in Q1 2026 and has held it in 3 quarters since. The position peaked at $978M in Q2 2026. 1,237 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

  • Dodge & Cox held 20,352,460 shares of Novo Nordisk worth $772M as of Q3 2026.
  • Dodge & Cox sold 44,650 Novo Nordisk shares in Q3 2026, an estimated $2.06M.
  • Novo Nordisk made up 0.41% of Dodge & Cox's portfolio in Q3 2026, its #72 holding.
  • Dodge & Cox first reported a position in Novo Nordisk in Q1 2026 and has held it in 3 quarters since.
  • Dodge & Cox's Novo Nordisk position peaked at $978M in Q2 2026.
  • 1,237 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Dodge & Cox's 13F filing for Q3 2026, filed 13 Nov 2026.